TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Leveraging Social Networks to Increase COVID-19 Testing Uptake

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Endorse opioid use in the past 6 months~* Speak English or Spanish~* Age 18+~Exclusion Criteria:~* Deny history of opioid use (but will be offered COVID-19 testing)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Chain Referral (Type: EXPERIMENTAL): In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing; these recruits are then trained to do the same.
- Credible Messenger (Type: EXPERIMENTAL): In the credible messenger intervention, peers identified as popular and socially influential individuals within their respective communities with lived experience are trained to engage within formal and informal social networks to promote behavior change.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin to Prevent Late Miscarriage and Preterm Delivery in Women With Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-45 years~* PCOS diagnosed or reconfirmed according to Rotterdam 2003 criteria, not more than 5 years prior to inclusion~* Mode of conception: Any~* Single, viable fetus, diagnosed by vaginal ultrasound~* Gestational week at inclusion: week 6 + 0 to 12 + 0~* Wash out for metformin: at least 7 days~* Able to communicate fluently in the official language at the study cite or English~Exclusion Criteria:~* Any type of diabetes (except GDM in former pregnancy)~* Known liver disease or ALAT \> 100 IU/L~* Known kidney disease or creatinine \> 110 μmol/L~* Known alcohol or drug abuse~* Use of drugs interfering with metformin: erytromycin (or other macrolides), cimetidine, anticoagulation therapy~* Unsuitable for participation of other reasons

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- metformin (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject was a Heart Failure subject who signed informed consent for MBG311, MBG312, or MBG312C.~* The subject was administered 123I-mIBG in MBG311, MBG312, or MBG312C.~* The subject completed the late planar imaging assessments (at a minimum) required by the protocols for MBG311, MBG312, or MBG312C.~* The subject agreed to allow the investigator access to medical records, including those relating to subject death should this occur.~Exclusion Criteria:~* The subject withdrew or was withdrawn from MBG311, MBG312, or MBG312C.~* The subject was considered lost-to-follow-up (6 months without contact) in MBG311, MBG312, or MBG312C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group (Type: None): No participants received any drug administration. No intervention conducted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subject aged \>=10 and \<19 years at the time of enrollment.~2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.~3. Negative urine pregnancy test for all female subjects.~Exclusion Criteria:~1. Previous vaccination with any meningococcal serogroup B vaccine.~2. Subjects who have received prior HAV vaccination.~3. Subjects who are scheduled to receive 1 or more doses of an HPV vaccine as part of a 3-dose series during the period between Visit 1 and 28 days after the second vaccination.~4. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.~5. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.~6. Significant neurological disorder or history of seizure (excluding simple febrile seizure).~7. Current chronic use of systemic antibiotics.~8. Received any investigational vaccines, drugs, or devices within 28 days before administration of the first study vaccination.~9. Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- rLP2086 lot 1 (Type: EXPERIMENTAL): None
- rLP2086 lot 2 (Type: EXPERIMENTAL): None
- rLP2086 lot 3 (Type: EXPERIMENTAL): None
- Control (Type: ACTIVE_COMPARATOR): Havrix (HAV) and Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of colorectal adenocarcinoma~* Diagnosis of metastatic disease~* RAS (NRAS and KRAS exon 2,3 and 4) wild-type in tissue at initial diagnosis~* Efficacy of a first line therapy containing an anti-EGFR agent (panitumumab or ceuximab) with a major response achieved (complete or partial response)~* Progression after a second line therapy~* Available and adequate baseline tumour tissue sample~* Measurable disease according to RECIST criteria v1.1~* Male or female patients \> 18 years of age~* ECOG Performance Status 0-1~* Life expectancy of at least 3 months~* Adequate bone marrow, liver and renal function~* If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 14 days before initiation of study treatment~* If female and of childbearing potential, or if male, agreement to use adequate contraception (eg, abstinence, intrauterine device, oral contraceptive, or double-barrier method)~* Signed informed consent~Exclusion Criteria:~* Any contraindication to use Trifluridine - Tipiracil or Panitumumab~* More than two previous lines of treatment~* Active uncontrolled infections~* Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix~* Pregnancy~* Breastfeeding~* Interstitial lung disease or pulmonary fibrosis~* Grade III or IV heart failure (NYHA classification)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Trifluridine-Tipiracil
- Arm B (Type: EXPERIMENTAL): Panitumumab + Trifluridine-Tipiracil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inflammation After One Lung Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20-70 years~* American Society of Anaesthesiologists (ASA) physical status I-III~* elective open lobectomy with OLV~Exclusion Criteria:~* history of drug hypersensitivity~* drug addiction~* treatment with psychotropic drugs~* severe psychiatric and central nerve system diseases~* persistent tobacco abuse, autoimmune system diseases~* diabetes mellitus~* cardiac failure (New York Heart Association class greater than 2)~* clinically relevant obstructive and restrictive lung diseases (vital capacity or forced expiratory volume in 1s lover than 50% of the predicted values)~* pulmonary hypertension (mean pulmonary arterial pressure grater than 25 mmHg)~* pre-existing coagulation disorders~* history of treatment with immunosuppressant drugs in the 4 weeks before surgery~* Patient with evidence of pulmonary or systemic infections (C-reactive protein serum concentration greater than 5 mg/L, leucocytosis greater than 10.0 bioparticles/L or body temperature greater than 37 stC)~* perioperative blood derivatives, steroids or non-steroidal anti-inflammatory drug (NSAID)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: EXPERIMENTAL): Sevoflurane group (S group)- The group anaesthesied with sevoflurane
- Propofol (Type: ACTIVE_COMPARATOR): Propofol 4-6 mg/kg/h iv

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female volunteers 18-60 years of age~Exclusion Criteria:~* Any auto-immune disease or other serious acute, chronic or progressive disease~* Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine~* History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine~* Within the past 7 days, they have experienced any acute disease or infections requiring systemic antibiotic or antiviral therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms (Type: EXPERIMENTAL): None
- MF59 adjuvant H5N1 influenza vaccine 15 micrograms (Type: EXPERIMENTAL): None
- non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Male or female between 21 and 75 years old~* Body Mass Index (BMI) of 25 or more~Exclusion Criteria:~* Chronic Liver disease other than NASH~* Uncontrolled diabetes~* Any major surgery within 6 weeks of screening~* Unable to self-administer under the skin injections~* Any bone trauma, fracture or bone surgery within 8 weeks of screening

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group A: BMS-986036 (Type: EXPERIMENTAL): Administered as specified on specified days
- Treatment Group B: BMS-986036 (Type: EXPERIMENTAL): Administered as specified on specified days
- Treatment Group C: Placebo (Type: PLACEBO_COMPARATOR): Administered as specified on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe stable COPD (Stage II or Stage III) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guideline.~Current or ex-smokers who have a smoking history of at least 10 pack years. Patients with a post-bronchodilator Forced Expiratory Volume in one second (FEV1) ≥ 30% and \< 80% of the predicted normal, and post-bronchodilator FEV1/FVC \< 0.7.~Modified Medical Research Council (mMRC) grade of at least 2 at Visit 2.~Exclusion Criteria:~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human Chorionic Gonadotropin (hCG) laboratory test.~Patents with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH), bladder-neck obstruction, moderate to severe renal impairment or urinary retention. BPH patients who are stable on treatment can be considered.~Patients with a history of long QT syndrome or whose QTc measured at run-in (Visit 2) (Fridericia method) is prolonged (\>450 ms for males and females) as confirmed by the central Electrocardiogram (ECG) assessor.~Patients with Type I or uncontrolled Type II diabetes. Patients who have not achieved spirometry result at Visit 2 in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) criteria for acceptability and repeatability.~Patients with, a) any history of asthma or, b) onset of respiratory symptoms prior to age 40 years.~Patients with concomitant pulmonary disease (e.g. lung fibrosis, primary bronchiectasis, sarcoidosis, interstitial lung disorder, pulmonary hypertension).~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 (Type: EXPERIMENTAL): QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg
- fluticasone/salmeterol (Type: ACTIVE_COMPARATOR): Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be aged 7 to \<18 years and have amblyopia associated with strabismus, anisometropia, or both.~* Visual acuity in the amblyopic eye must be 20/40 to 20/400 inclusive and visual acuity in the sound eye must be 20/25 or better.~Exclusion Criteria:~* Patients must not have received amblyopia treatment (other than spectacles) in the past month or more than one month of amblyopia treatment in the last 6 months.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Effect of Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With Chronic Anal Fissures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consenting patients of either sex.~* Between 18 and 75 years of age.~* With a single, chronic, posterior midline anal fissure.~* Defined as having anal pain for the 6 weeks prior to Screening.~Exclusion Criteria:~* More than one anal fissure.~* A fistula-in-ano or anal abscess.~* Inflammatory bowel disease.~* Fibrotic anal stenosis.~* Anal fissure secondary to an underlying condition.~* Any anal surgery.~* Concomitant medication that may interfere with study evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cellegesic (nitroglycerin 0.4%) (Type: EXPERIMENTAL): Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
- Placebo 375 mg (Type: PLACEBO_COMPARATOR): Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study Of Lamictal In Neurotic Excoriation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* men and women age 18-65~* current diagnosis of neurotic excoriation~Exclusion Criteria:~* unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination~* history of seizures~* myocardial infarction within 6 months~* current pregnancy or lactation, or inadequate contraception in women of childbearing potential~* a need for medication other than Lamictal with possible psychotropic effects or unfavorable interactions with Lamictal~* clinically significant suicidality~* lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder~* current or recent (past 3 months) DSM-IV substance abuse or dependence~* illegal substance use within 2 weeks of study initiation~* initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline~* previous treatment with Lamictal~* treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline~* current treatment with an anti-epileptic medication and~* patients who have previously been diagnosed with a medical condition that cause skin itchiness (e.g. liver, kidney, and blood diseases, etopic allergies)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Patients with refractory, recurrent or relapsing C. difficile infection (CDI) defined as EITHER:~  * At least three episodes of mild-to-moderate CDI~ * At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity~ * One protracted episode of CDI, defined as at least 3 weeks of ongoing Grade 3 severe symptoms of CDI despite standard antimicrobial therapy for CDI~ * We expect that most, but not all, subjects will have tried and failed a taper of vancomycin.~* Willingness to accept risk of unrelated donor stool~* Age 7 and above. Seven is chosen as a lower limit based upon the legal age of assent. Based on the literature, most children aged 7 and above can be taught to swallow even large capsules through simple coaching techniques~* Able to consent for self, or parental assent/child assent as age appropriate~Exclusion criteria~* Delayed gastric emptying syndrome~* Known chronic aspiration~* Swallowing dysfunction or oral-motor dyscoordination.~* Inability or unwillingness to swallow multiple large capsules~* Pregnant women~* Patients with an acute illness unrelated to CDI or an acute exacerbation of underlying comorbid condition~* Patients with comorbidities associated with increased risk of serious infection following bacterial translocation, including but not limited to:~  * subjects on major immunosuppressive agents including high dose corticosteroids, calcineurin inhibitors, mTOR inhibitors, lymphocyte depleting biologic agents, anti-TNF agents, and others; chemotherapeutic anti-neoplastic agents\*~ * Patients with decompensated liver cirrhosis, advanced HIV/AIDS, recent bone marrow transplant, hypoglobulinemia or other cause of severe immunodeficiency\*~* Patients with a history of significant allergy to foods not excluded from the donor diet

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Capsule (Type: EXPERIMENTAL): Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via frozen capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete